FdaApplication
NDA 214787
Identifiers
- fda_app_no: NDA214787
Properties
| Property | Value |
|---|---|
| applicant_name | GILEAD SCIENCES INC |
| application_type | NDA |
| approval_date | 2020-10-22 |
Revenue by product
VEKLURY
| Period | Revenue |
|---|---|
| Q2 2026 | $23.0M |
| Q1 2026 | $144.0M |
| Q4 2025 | $211.0M |
| Q3 2025 | $277.0M |
| Q2 2025 | $121.0M |
| Q1 2025 | $302.0M |
| Q4 2024 | $338.0M |
| Q3 2024 | $692.0M |
| Q2 2024 | $214.0M |
| Q1 2024 | $555.0M |
| Q4 2023 | $719.0M |
| Q3 2023 | $636.0M |
| Q2 2023 | $256.0M |
| Q1 2023 | $573.0M |
| Q4 2022 | $1.0B |
| Q3 2022 | $925.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VEKLURY | REMDESIVIR | 100MG/20ML (5MG/ML) | SOLUTION;INTRAVENOUS |
| VEKLURY | REMDESIVIR | 100MG/VIAL | POWDER;INTRAVENOUS |
2 products